BMC Infectious Diseases (May 2023)

Risk factors for SARS-CoV-2 seropositivity in a health care worker population during the early pandemic

  • Sebastian D. Schubl,
  • Cesar Figueroa,
  • Anton M. Palma,
  • Rafael R. de Assis,
  • Aarti Jain,
  • Rie Nakajima,
  • Algimantas Jasinskas,
  • Danielle Brabender,
  • Sina Hosseinian,
  • Ariana Naaseh,
  • Oscar Hernandez Dominguez,
  • Ava Runge,
  • Shannon Skochko,
  • Justine Chinn,
  • Adam J. Kelsey,
  • Kieu T. Lai,
  • Weian Zhao,
  • Peter Horvath,
  • Delia Tifrea,
  • Areg Grigorian,
  • Abran Gonzales,
  • Suzanne Adelsohn,
  • Frank Zaldivar,
  • Robert Edwards,
  • Alpesh N. Amin,
  • Michael J. Stamos,
  • Philip S. Barie,
  • Philip L. Felgner,
  • Saahir Khan

DOI
https://doi.org/10.1186/s12879-023-08284-y
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background While others have reported severe acute respiratory syndrome-related coronavirus 2(SARS-CoV-2) seroprevalence studies in health care workers (HCWs), we leverage the use of a highly sensitive coronavirus antigen microarray to identify a group of seropositive health care workers who were missed by daily symptom screening that was instituted prior to any epidemiologically significant local outbreak. Given that most health care facilities rely on daily symptom screening as the primary method to identify SARS-CoV-2 among health care workers, here, we aim to determine how demographic, occupational, and clinical variables influence SARS-CoV-2 seropositivity among health care workers. Methods We designed a cross-sectional survey of HCWs for SARS-CoV-2 seropositivity conducted from May 15th to June 30th 2020 at a 418-bed academic hospital in Orange County, California. From an eligible population of 5,349 HCWs, study participants were recruited in two ways: an open cohort, and a targeted cohort. The open cohort was open to anyone, whereas the targeted cohort that recruited HCWs previously screened for COVID-19 or work in high-risk units. A total of 1,557 HCWs completed the survey and provided specimens, including 1,044 in the open cohort and 513 in the targeted cohort. Demographic, occupational, and clinical variables were surveyed electronically. SARS-CoV-2 seropositivity was assessed using a coronavirus antigen microarray (CoVAM), which measures antibodies against eleven viral antigens to identify prior infection with 98% specificity and 93% sensitivity. Results Among tested HCWs (n = 1,557), SARS-CoV-2 seropositivity was 10.8%, and risk factors included male gender (OR 1.48, 95% CI 1.05–2.06), exposure to COVID-19 outside of work (2.29, 1.14–4.29), working in food or environmental services (4.85, 1.51–14.85), and working in COVID-19 units (ICU: 2.28, 1.29–3.96; ward: 1.59, 1.01–2.48). Amongst 1,103 HCWs not previously screened, seropositivity was 8.0%, and additional risk factors included younger age (1.57, 1.00-2.45) and working in administration (2.69, 1.10–7.10). Conclusion SARS-CoV-2 seropositivity is significantly higher than reported case counts even among HCWs who are meticulously screened. Seropositive HCWs missed by screening were more likely to be younger, work outside direct patient care, or have exposure outside of work.

Keywords